EA200401478A1 - Монооксид углерода в качестве биомаркера и лекарственного средства - Google Patents

Монооксид углерода в качестве биомаркера и лекарственного средства

Info

Publication number
EA200401478A1
EA200401478A1 EA200401478A EA200401478A EA200401478A1 EA 200401478 A1 EA200401478 A1 EA 200401478A1 EA 200401478 A EA200401478 A EA 200401478A EA 200401478 A EA200401478 A EA 200401478A EA 200401478 A1 EA200401478 A1 EA 200401478A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lung
diseases
biomarker
carbon monoxide
disease
Prior art date
Application number
EA200401478A
Other languages
English (en)
Russian (ru)
Inventor
Августин М.К. Чой
Лео Е. Оттербейн
Original Assignee
Йейл Юниверсити
Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йейл Юниверсити, Джонс Хопкинс Юниверсити filed Critical Йейл Юниверсити
Publication of EA200401478A1 publication Critical patent/EA200401478A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA200401478A 2002-05-09 2002-05-09 Монооксид углерода в качестве биомаркера и лекарственного средства EA200401478A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
EA200401478A1 true EA200401478A1 (ru) 2005-12-29

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401478A EA200401478A1 (ru) 2002-05-09 2002-05-09 Монооксид углерода в качестве биомаркера и лекарственного средства

Country Status (13)

Country Link
EP (1) EP1501523A4 (sr)
JP (1) JP2005532314A (sr)
KR (1) KR20040106515A (sr)
CN (1) CN1638781A (sr)
AU (1) AU2002308676B2 (sr)
BR (1) BR0215717A (sr)
CA (1) CA2484770A1 (sr)
EA (1) EA200401478A1 (sr)
MX (1) MXPA04011113A (sr)
NO (1) NO20044865L (sr)
RS (1) RS96904A (sr)
UA (1) UA84402C2 (sr)
WO (1) WO2003094932A1 (sr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
WO2003088981A1 (en) 2002-04-15 2003-10-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods of treating necrotizing enterocolitis
EA200401365A1 (ru) 2002-04-15 2005-04-28 Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Способы лечения илеуса
EA200401525A1 (ru) * 2002-05-17 2006-06-30 Йейл Юниверсити Способы лечения гепатита (варианты )
JP2005345242A (ja) * 2004-06-02 2005-12-15 Tohoku Univ 肺癌の化学療法治療効果の評価方法
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
EP2099439A2 (en) * 2006-12-06 2009-09-16 Alfama - Investigação E Desenvolvimento De Produto Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (ja) 2008-06-12 2010-04-30 Keio Gijuku バイオマーカーとしてのマイクロｒｎａを用いた頭頸部腫瘍の診断・治療選択
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CN109925318A (zh) * 2011-01-14 2019-06-25 洛杉矶儿童医院 用于治疗包括镰状细胞疾病的疾病的一氧化碳溶液
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9359197B2 (en) 2011-03-24 2016-06-07 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring parkinson's disease
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
ES2628634T3 (es) 2011-07-21 2017-08-03 Alfama, Inc. Moléculas liberadoras de monóxido de carbono-rutenio y usos de las mismas
WO2014165732A1 (en) 2013-04-04 2014-10-09 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (zh) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 用以改良器官功能及延長器官移植物壽命之系統及方法
JP7161737B2 (ja) * 2017-01-30 2022-10-27 哲也 石川 悪性腫瘍の検査方法
WO2019235165A1 (ja) 2018-06-08 2019-12-12 住友精化株式会社 炎症性消化器官疾患用組成物
EP3804731A4 (en) * 2018-06-08 2022-04-06 Sumitomo Seika Chemicals Co., Ltd. COMPOSITION FOR SKIN WOUNDS
US12370210B2 (en) * 2019-06-06 2025-07-29 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
US20230346831A1 (en) * 2020-07-16 2023-11-02 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (de) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, die Kohlenmonoxid-Quellen darstellen, Verfahren zu seiner Herstellung und seine Verwendung
DK0921807T3 (da) * 1996-08-27 2004-03-15 Messer Griesheim Gmbh Hydrogenholdigt lægemiddel
CA2442457A1 (en) * 2001-03-30 2002-10-10 Roland Buelow Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Also Published As

Publication number Publication date
EP1501523A1 (en) 2005-02-02
EP1501523A4 (en) 2006-12-13
AU2002308676A1 (en) 2003-11-11
JP2005532314A (ja) 2005-10-27
RS96904A (sr) 2007-02-05
CA2484770A1 (en) 2003-11-20
CN1638781A (zh) 2005-07-13
WO2003094932A1 (en) 2003-11-20
AU2002308676B2 (en) 2009-06-11
BR0215717A (pt) 2005-02-22
UA84402C2 (ru) 2008-10-27
NO20044865L (no) 2004-12-07
KR20040106515A (ko) 2004-12-17
MXPA04011113A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
EA200401478A1 (ru) Монооксид углерода в качестве биомаркера и лекарственного средства
Nayyar et al. Defining and characterizing severe hypoxemia after liver transplantation in hepatopulmonary syndrome
Rodman et al. Alveolar hypoventilation due to involvement of the respiratory center by obscure disease of the central nervous system
DE602004008927D1 (de) Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
ATE296056T1 (de) Atemfunktionsanalyse mittels kapnographie
EA199900669A1 (ru) Промежуточные соединения для получения замещенных n-[аминоиминометил или аминометил)фенил]пропиламидов
EA199800690A1 (ru) Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот
MX2023002522A (es) Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii.
NO20052987L (no) Forbindelser for normalisering av sovn/vaken-syklusen.
Perry et al. Cerebral function before and after carotid endarterectomy.
EA200001192A1 (ru) Каберголин и прамипексол для лечения заболевания цнс, особенно болезни паркинсона
Sahin et al. The effect of hyperbaric oxygen therapy on erectile functions: a prospective clinical study
RU2010100484A (ru) Новые соединения 892
EA200200518A1 (ru) Способ и композиция для лечения заболеваний легких
Lemko et al. The usage of haloaerosoltherapy in the rehabilitational treatment of children with reccurent bronchitis
Zhang et al. Experience of Hypoxic Conditioning in Rehabilitation Programs for Patients with Chronic Occupational Lung Diseases: a Pilot Study
RU2005115102A (ru) Новые противоопухолевые соединения
Maggini et al. Psychological and physiopathological study on coronary patients
Liang et al. Anesthetic Effects and Safety of Remimazolam Tosilate in Elderly Patients With Hip Fractures: A Retrospective Cohort Study
Dvojković et al. Sialoendoscopy in children
Lipford et al. 0587 Demographic characteristics and comorbidities of patients with narcolepsy: a propensity score–matched cohort study
SU602190A1 (ru) Способ лечени воспалительно-нагнетательных заболеваний
RU2142768C1 (ru) Способ лечения пневмокониозов
Mihaltan et al. Effects of a new Airway Clearance Technology versus manual physiotherapy in COPD
Javorac et al. Tracheobronchopathia Osteochondroplastica: A Study of 22 Patients from Serbia